Eli Lilly to Buy Calytrix Bio for Up to $1.5 Billion

Eli Lilly to Buy Calytrix Bio for Up to $1.5 Billion

来源:WSJ发布于 2026-11-16

Calytrix Bio, a privately held biotechnology company backed by JPMorgan Chase, is developing therapies aimed at a group of rare blood cancers.

相关标的:LLY

本文内容来自外部来源,点击「继续访问」将跳转到原始发布站点。